Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crestor Label Lends Validity To Controversial C-Reactive Protein Test

Executive Summary

FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say

You may also be interested in...



Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test

'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.

Where Cholesterol Surrogates Stand After ACC '16

Failure of another CETP inhibitor – Lilly’s evacetrapib – despite robust LDL-lowering raises more doubt about surrogates, yet doesn’t put too much of a damper on PCSK9 inhibitors at the annual American College of Cardiology meeting. Statins get another boost just ahead of entry of Crestor generics.

Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends

In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.

Related Content

Topics

UsernamePublicRestriction

Register

PS051928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel